36 reports

  • 6.1 INTRODUCTION
  • FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016-2023 (USD MILLION)

PREBIOTICS RESIST GASTRIC ACIDITY AND HYDROLYSIS CAUSED BY ENZYMES AND GASTROINTESTINAL ABSORPTION.

  • Mineral Supplement
  • United States
  • Market Size
  • Arla Foods
  • Cargill Inc.

One of the major reasons for the high bioavailability of organic minerals is that, unlike inorganic minerals, these do not interact with fiber, tannin, phytate, silicates, oxalate, or other minerals in the gastrointestinal tract.

  • Mineral Supplement
  • Pig
  • World
  • Alltech Inc.
  • Kemin Industries, Inc.

THE MICROPEARLS SPRAY FREEZING TECHNOLOGY ALLOWS FOR THE TIMELY RELEASE OF THESE ## KEY NUTRIENTS THROUGHOUT AN ANIMAL' S GASTROINTESTINAL TRACT.

  • Mineral Supplement
  • North America
  • United States
  • World
  • Market Size
  • VITAMIN & MINERAL PREMIXES MARKET, BY FUNCTIONALITY

Q. ##.

  • Mineral Supplement
  • World
  • Market Size
  • Glanbia plc
  • Nutreco N.V.

MARKET ##.

  • Mineral Supplement
  • APAC
  • Japan
  • World
  • Demand
  • 7.1 Nutrition/Therapeutic

TABLE OF CONTENTS ##.

  • Mineral Supplement
  • Archer Daniels Midland Company
  • Boehringer Ingelheim GmbH
  • Darling Ingredients Inc.
  • DuPont

You can easily book an appointment with one online.

  • Mineral Supplement
  • World
  • Market Size
  • Alltech Inc.
  • Kemin Industries, Inc.

It is used to enhance rumen and gastrointestinal tract function.

  • Cattle
  • Mineral Supplement
  • World
  • Market Size
  • Nutreco N.V.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Mineral Supplement
  • China
  • Demand
  • Amway Corporation
  • Joincare Pharmaceutical Group Industry Co., Ltd.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Energy
  • Mineral Supplement
  • Vitamin
  • China
  • Demand

MARKET SEGMENTATION ##.

  • Mineral Supplement
  • Argentina
  • Croda International Plc
  • Danone SA
  • General Mills, Inc.

The alleviation of gastrointestinal morbidity and other diseases in livestock, such as swine dysentery and acidosis in ruminants, is another advantage of feed ingredients enzymes.

  • Mineral Supplement
  • Colombia
  • South America
  • Market Size
  • Alltech Inc.

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Cancer Hormonal Therapy
  • Mineral Supplement
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

It is estimated that worldwide one in five men and one in three women are at risk of an osteoporotic fracture.

  • Mineral Supplement
  • World
  • Forecast
  • Quidel Corporation
  • Roche Group

THE MOST COMMON GRADE ##-## ADVERSE EVENTS INCLUDED NEUTROPENIA (##%), HYPOKALEMIA (##%), HYPOPHOSPHATEMIA (##%), RASH (##%), TUMOR FLARE (##%) AND GASTROINTESTINAL COMPLAINTS (##%).

  • Cancer Hormonal Therapy
  • Targeted Therapy
  • United States
  • Demand
  • Celgene Corporation

The subsidiary is focused on aging care, critical care & surgery, gastrointestinal function, and pediatrics.

  • Mineral Supplement
  • North America
  • United States
  • Demand
  • Market Size

Q. ##.

  • Mineral Supplement
  • United States
  • Cargill Inc.
  • Koninklijke DSM N.V.
  • Nutreco N.V.

OPROZOMIB IS ASSOCIATED WITH GASTROINTESTINAL TOXICITIES, WITH THE MOST COMMON GRADE ## AES BEING DIARRHEA, NAUSEA, AND VOMITING.

  • Cancer Hormonal Therapy
  • Market Size
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Novartis AG

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Janssen Biotech, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Janssen Biotech, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • United States
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Mineral Supplement
  • United States
  • World
  • Product Initiative

Common toxicities were hematological and gastrointestinal.

  • Cancer Hormonal Therapy
  • Mineral Supplement
  • Oncology
  • United States
  • Acetylon Pharmaceuticals, Inc.
  • 5. All the trials included are unique trials.

Patients were randomized ##:## to receive PVd or Vd.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Mineral Supplement
  • Oncology
  • Celgene Corporation
  • 1.1 MARKET DEFINITION

Such drugs with sensorial effects are mainly developed in the cough, cold & allergy and gastrointestinal categories.

  • Mineral Supplement
  • OTC
  • Spain
  • Forecast
  • Sanofi S.A.

Gastrointestinal-related AEs were infrequent and low grade.

  • Cancer Hormonal Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • Karyopharm Therapeutics Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## Prothena Corp Plc ## ## ## ## Johnson & Johnson ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## TheraPharm Deutschland GmbH ## ## ## ## Spectrum Pharmaceuticals Inc ## ## ## ## GlaxoSmithKline Plc ## ## ##

  • Cancer Hormonal Therapy
  • Cell Therapy
  • Endocrine Disease
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Patients were randomized ##:## to receive PVd or Vd.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Mineral Supplement
  • Oncology
  • Celgene Corporation

The prominent features of this report are - ##.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Mineral Supplement
  • World
  • Celgene Corporation